Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074922 | 0.86 | PTGS1 (0.58) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL31353034 | 0.82 | PTGS1 (0.62) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL24075809 | 0.82 | PTGS1 (0.62) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL9356468 | 0.82 | PTGS1 (0.53) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL9356461 | 0.82 | PTGS1 (0.53) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL7077134 | 0.79 | PTPN1 (0.51) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL7048351 | 0.79 | PTPN1 (0.51) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL1258943 | 0.78 | PTGS1 (0.50) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL16466570 | 0.78 | PTGS1 (0.47) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL16466568 | 0.78 | PTGS1 (0.47) | PTGS1PDE4ASNCAPDE3APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778661-B1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY ALPHA-TOCOPHEROL AND ALKANOATES THEREOF | DSM IP ASSETS BV (NL) | 2014-01-22 | — | — | EP | disclosed |
| US-8431727-B2 | Process for the manufacture of chroman derivatives, especially α-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2013-04-30 | — | — | US | disclosed |
| CN-101704809-B | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | DSM IP ASSETS BV | 2012-11-07 | — | — | CN | disclosed |
| CN-1968943-B | Process for producing chroman derivatives, especially alpha-tocopherol and alkanoates thereof | DSM IP ASSETS BV | 2011-08-10 | — | — | CN | disclosed |
| CN-101704809-A | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | DSM IP ASSETS BV | 2010-05-12 | — | — | CN | disclosed |
| US-7696364-B2 | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | DSM IP Assets B.V. a Netherlands Corporation (NL) | 2010-04-13 | — | — | US | disclosed |
| CN-100586915-C | Process for preparing alkenylated hydroxylated aromatic compounds, chroman compounds and acylated derivatives thereof | DSM IP ASSETS BV | 2010-02-03 | — | — | CN | disclosed |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2009-07-09 | — | — | US | disclosed |
| EP-1689733-B1 | PROCESS FOR THE MANUFACTURE OF ALKENYLATED HYDROXYLATED AROMATIC COMPOUNDS, OF CHROMAN COMPOUNDS AND OF THEIR ACYLATED DERIVATIVES | DSM IP ASSETS BV (NL) | 2008-10-15 | — | — | EP | disclosed |
| CN-1968943-A | Process for producing chroman derivatives, especially alpha-tocopherol and alkanoates thereof | DSM IP ASSETS BV (NL) | 2007-05-23 | — | — | CN | disclosed |
| US-20020010347-A1 | Preparation of d,l-alpha-tocopherol | ROCHE VITAMINS INC. | 2002-01-24 | — | — | US | disclosed |
| US-20010027255-A1 | Tocopherol manufacture by tris(perfluorohydrocarbylsulphonyl) methane or metal methides thereof | F. HOFFMANN-LA ROCHE AG | 2001-10-04 | — | — | US | disclosed |
| EP-1134218-A1 | Process for manufacturing (all-rac.)-alpha-Tocopherol | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-19 | — | — | EP | disclosed |
| US-6066745-A | ACID-CATALYZED CONDENSATION OF TRIMETHYLHYDROQUINONE WITH ISOPHYTOL IN THE PRESENCE OF AT MOST 0.4 WEIGHT PERCENT BASED ON THE WEIGHT OF ISOPHYTOL OF A SULPHUR-CONTAINING ACID CATALYST | ROCHE VITAMINS INC. (US) | 2000-05-23 | — | — | US | disclosed |
| EP-1000940-A1 | Process for manufacturing d,l-alpha-tocopherol | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| EP-0970953-A1 | Manufacture of d,1-alpha-tocopherol | F. Hoffmann-La Roche AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| EP-0949255-A1 | Process for manufacturing d, 1-alpha-tocopherol in a carbonate solvent and in the presence of a sulphur-containing acid catalyst | F. HOFFMANN-LA ROCHE AG (CH) | 1999-10-13 | — | — | EP | disclosed |
| EP-0937055-A2 | PROCESS FOR MANUFACTURING d,1-ALPHA-TOCOPHEROL | F. HOFFMANN-LA ROCHE AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| US-5908939-A | CONDENSATION OF TRIMETHYLHYDROQUINONE WITH ISOPHYTOL COMPRISES CARRYING OUT THE CONDENSATION IN THE PRESENCE OF BIS-(TRIFLUOROMETHYLSULPHONYL)AMINE OR A METAL SALT THEREOF | ROCHE VITAMINS INC. (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1998021197-A2 | PROCESS FOR MANUFACTURING d,l-α-TOCOPHEROL | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027255-A1 | Tocopherol manufacture by tris(perfluorohydrocarbylsulphonyl) methane or metal methides thereof | TTPA, TST, TTR | PTGS1 558/4885PDE4A 4781/4885SNCA 2862/4885 |
| US-20020010347-A1 | Preparation of d,l-alpha-tocopherol | NFE2L2, VDR, NDUFB3 | PTGS1 1102/4885PDE4A 4850/4885SNCA 1798/4885 |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | TTPA, TCP1, TBL2 | PTGS1 990/4885PDE4A 4382/4885SNCA 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.